These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27572663)

  • 1. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
    Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
    Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
    Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
    Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RARβ Promoter Methylation as an Epigenetic Mechanism of Gene Silencing in Non-small Cell Lung Cancer.
    Dutkowska A; Antczak A; Pastuszak-Lewandoska D; Migdalska-Sek M; Czarnecka KH; Górski P; Kordiak J; Nawrot E; Brzeziańska-Lasota E
    Adv Exp Med Biol; 2016; 878():29-38. PubMed ID: 26453065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
    Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
    J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
    Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
    Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
    Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients.
    Pastuszak-Lewandoska D; Kordiak J; Migdalska-Sęk M; Czarnecka KH; Antczak A; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska D; Brzeziańska-Lasota E
    Respir Res; 2015 Jun; 16(1):76. PubMed ID: 26112163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
    Wu X; Wu G; Yao X; Hou G; Jiang F
    Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
    Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
    Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
    Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
    Yan W; Xu N; Han X; Zhou XM; He B
    Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assessment of the diagnostic role of FHIT promoter methylation in non-small cell lung cancer.
    Geng X; Pu W; Tan Y; Lu Z; Wang A; Tan L; Chen S; Guo S; Wang J; Chen X
    Oncotarget; 2017 Jan; 8(4):6845-6856. PubMed ID: 28036263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FHIT, EGFR, and MSH2: possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in Egyptian patients.
    Younes SF; Aiad HA; Asaad NY; Kandil MA; Natkunam Y; Mokhtar NM
    Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):275-83. PubMed ID: 24185125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
    Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L
    Cancer Res; 1999 Oct; 59(19):4798-803. PubMed ID: 10519387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project.
    Verri C; Roz L; Conte D; Liloglou T; Livio A; Vesin A; Fabbri A; Andriani F; Brambilla C; Tavecchio L; Calarco G; Calabrò E; Mancini A; Tosi D; Bossi P; Field JK; Brambilla E; Sozzi G;
    Am J Respir Crit Care Med; 2009 Mar; 179(5):396-401. PubMed ID: 19096006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood.
    Tan S; Sun C; Wei X; Li Y; Wu Y; Yan Z; Feng F; Wang J; Wu Y
    Exp Lung Res; 2013; 39(4-5):182-90. PubMed ID: 23614702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC.
    Pesta M; Kulda V; Topolcan O; Safranek J; Vrzalova J; Cerny R; Holubec L
    Anticancer Res; 2009 Nov; 29(11):4535-9. PubMed ID: 20032402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.